About us

Our Passion

What unites us at Rentschler, is the passion for what we do. As a full-service CDMO we are your outsourcing partner for the bioprocess development, cGMP manufacturing and aseptic filling of biopharmaceuticals as well as for the elaboration of approval strategies for your products. Thanks to our many years of experience, the quality of our consulting services, and our expertise in finding solutions, we are among the top suppliers in our field.

Founded in 1927, Rentschler is a privately owned and independent company. Our company structure guarantees rapid decision-making and efficient, smooth-running processes, and consequently keeping project timelines.
Already in the early beginnings of biotechnology, Rentschler has built up a reputation with the development of different Interferon products (Fiblaferon, Polyferon).

Nowadays, our attention is firmly focused on your products. For the success of your project we can refer to our experience in various molecules like antibodies, fusion proteins or enzymes. Thanks to our focus on innovations, we are always on the cutting edge of technologies.

Our Mission Statement

Our Conviction

We provide an important contribution to biopharmaceuticals, thereby help millions of people each day. We are among the best in the industry and set new standards in client focus, individual customized solutions and reliability. This is precisely what the Rentschler brand stands for and we are proud of it. Within just a few years, we have become a leading company in our field. This confirms our ability to perform both now and in future.

Client Benefit

We successfully lead projects for our clients, thus ensuring their competitiveness in the markets. We deliver products according to their needs and timelines. Every project with Rentschler is in expert hands. For our clients, the Rentschler brand stands for expertise in finding solutions, years of experience, innovation, independence, quality of our consulting services and fastest possible time to market. Thus, we minimize the business risk of our demanding global clientele.

Our Business Objective

We are known worldwide as "THE BIOPHARMA MANUFACTURER".
We make an essential contribution to the global availability of biopharmaceuticals. We generate sufficient earning power and liquidity, which enables us to remain a solid, privately owned, medium-sized company and be able to act independently over the long term.

Management

Dr. Frank Mathias,
Chief Executive Officer
Stefan Rampf,
Chief Financial Officer
Thomas Siklosi,
Chief Operating Officer

Short CV

Short CV

Short CV

Dr. Frank Mathias studied pharmacy at the Paris VI University where he graduated in the field of immunology in 1991. He has gained more than 25 years’ experience in leading positions in the pharmaceutical and biotech industry. His professional career began when he assumed a position as International Product Manager at Hoechst AG. After that, he became General Manager of the successful and renowned companies Servier Deutschland and Amgen GmbH in Munich. Dr. Frank Mathias was Chief Executive Officer of the Medigene AG from May 2009 until January 2016. He joined the company in 2008 as Chief Operating Officer taken the responsibility for Marketing, Sales and Business Development. In addition, he is Chairman of vfa bio which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies. Since April 1st, 2016 Dr. Frank Mathias has been Chief Executive Officer of Rentschler Biotechnologie GmbH.

Stefan Rampf studied Business Administration and started his career in the audit area of Ernst & Young in 1991. After 7 years, he moved to TA Triumph-Adler AG where he has held different positions up to Head of Controlling. Subsequently, Stefan Rampf became CFO of Triumph-Adler A-Vi-Tec Group and held the position from 2001 to 2004. He continued his successful carrier as Finance Director at De La Rue Cash Systems GmbH and Volvo Financial Services GmbH. After that, Stefan Rampf joined the company ABL-TECHNIC Entlackung GmbH in 2013 as CFO. During his career he has acquired a wealth of management experience in different areas, including the set up of finance departments as active business partner for both single legal entities as well as larger groups. Since May 1st, 2016 Stefan Rampf has been Chief Financial Officer of Rentschler Biotechnologie.

Thomas Siklosi obtained his degree in chemical engineering (Dipl.-Ing.) from the Universities of Applied Sciences in Isny and Munich. He started his career at Boehringer Mannheim where he was responsible for the development of manufacturing processes. In June 1984 Thomas Siklosi joined Rentschler Biotechnologie GmbH as Head of Active Ingredient Manufacturing. He was responsible for the cell culture manufacturing of proteins for clinical studies as well as for protein purification. In 2002 he became Head of the Department Protein Chemistry. Thanks to his successful work and many years of experience he became Senior Vice President of entire cGMP Operations in 2008. Since September 2012 he has been Chief Operating Officer where he took over the responsibility for the Process Development and cGMP Manufacturing (Upstream and Downstream Processing, Aseptic Filling, Technical Services), Quality Management as well as Operational Excellence.

Facts and Figures

Our company

  • Medium-sized, privately owned company
  • Since founded in 1927, the company is owned by the family Rentschler
  • Chairman of the supervisory board is
    Dr. Nikolaus F. Rentschler
  • Headquarters: Laupheim, Germany
  • Gross area: more than 40,000 m²
  • Biotechnology pioneer
  • Full-service contract supplier
  • Contract development and manufacturing of biopharmaceuticals in mammalian cell culture

For further information please have a look at our press releases and announcements or our company brochure:

Our clients

  • We are the outsourcing partner for more than 100 clients worldwide
  • Small, Mid and Big Pharma and Biotech companies have been working with us
  • We offer reliable and detailed consulting services
  • A significant proportion of our clients relied on us for many years and work together with us on several projects

Our track record

  • Expertise with over 200 different molecules
  • Over 250 batches in active pharmaceutical ingredient manufacturing
  • For about 30 % of our cell culture processes we use continuous mode
  • Successful implementation of single-use bioreactors and single-use materials for protein purification
  • Constant and continuous expansion of capacity in process development, manufacturing and quality control

Quality and Sustainability

Quality is an overall concept of Rentschler: Competent consulting in the beginning, followed by the project design up to implementation and reliable production of the drug substance or the drug product. Our manufacturing of active pharmaceutical ingredients in state-of-the-art cGMP facilities meets the highest standards of the biopharmaceutical industry. In order to guarantee this, we have high quality standards on our internal cooperation, on our team.
The quality of our performance and results is ensured by comprehensive quality management and precise and reliable quality control. In doing so, we pay attention to continuous monitoring and the adaptation of our quality standards.
Our goal is to enable you to bring to market as quickly as possible a product with the desired therapeutic effect, at the requested level of quality, and in the amount required.

Not only do we make the highest demands on the quality of our work, but also on our relationship with the environment. In our production, we pay attention not only to significantly reducing our quantities of trash but also using the most energy-efficient appliances. We have also operated our own Combined Heat and Power Plant since 2013 on our corporate premises. This facility enables us to produce up to 80 % of our own power supply. Additional diesel emergency generators allow us to be completely self-sufficient, if necessary. This allows us to ensure that manufacturing processes can go on as usual and maintain the quality of our work even during a power blackout.

In addition to ensuring security of our power supply, the CHP provides sustainable and environmentally friendly heat and steam for our manufacturing facilities, and as a result, we reduce CO2 emissions by approximately 2,500 tons annually.

Milestones in Rentschler's History

1927

Foundation as a pharmaceutical manufacturer

Foundation as a pharmaceutical manufacturer

Foundation as a pharmaceutical manufacturer

1974

Installation of the biotechnology division

Installation of the biotechnology division

Installation of the biotechnology division

1979

Start working with recombinant cell lines

Start working with recombinant cell lines

Start working with recombinant cell lines

1983

World´s first market approval for a natural Interferon-ß (Fiblaferon)

World´s first market approval for a natural Interferon-ß (Fiblaferon)

World´s first market approval for a natural Interferon-ß (Fiblaferon)

1989

Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel

Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel

Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel

1997

Entering the business of contract development and manufacturing of biopharmaceuticals

Entering the business of contract development and manufacturing of biopharmaceuticals

Entering the business of contract development and manufacturing of biopharmaceuticals

2006

Foundation of Rentschler Inc.

Foundation of Rentschler Inc.

Foundation of Rentschler Inc.

2008

Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)

Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)

Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)

2013

Implementing of own Combined Heat and Power plant

Implementing of own Combined Heat and Power plant

Implementing of own Combined Heat and Power plant

2014

First project with the TurboCell™ technology platform

First project with the TurboCell™ technology platform

First project with the TurboCell™ technology platform

2015

Manufacturing starts in the first 2,000 L single-use bioreactor

Manufacturing starts in the first 2,000 L single-use bioreactor

Manufacturing starts in the first 2,000 L single-use bioreactor

2016

Planned inauguration of the 2 x 3,000 L Twin facility

Second 2,000 L single-use bioreactor

Planned inauguration of the 2 x 3,000 L Twin facilitySecond 2,000 L single-use bioreactor

Planned inauguration of the 2 x 3,000 L Twin facility

Second 2,000 L single-use bioreactor